Navigation Links
Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
Date:9/8/2013

patients testing positive for allergies.

Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyper-responsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, and increased inflammation) when airways are exposed to various risk factors. Common triggers include exposure to allergens (e.g. house dust mites, animal fur, pollens and molds), smoke, chemical fumes, respiratory (viral) infections, exercise, strong emotional expressions, chemical irritants, and drugs (such as aspirin and beta blockers). Symptoms include recurring episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning.

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com 

This foregoing press
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. How plants sense gravity -- a new look at the roles of genetics and the cytoskeleton
2. Frontiers launches new open-access journal in Bioengineering and Biotechnology
3. AAPS announces 2013 National Biotechnology Conference award winners
4. 2013 AAPS National Biotechnology Conference returns to San Diego
5. Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award
6. Karl Deisseroth, Gero Miesenböck and Edward Boyden win Brandeis Gabbay Award in Biotechnology
7. Top 10 ways biotechnology could improve our everyday life
8. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
9. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
10. UMN scientists get federal grant for biotechnology development to purify fracking water
11. Biomass characterization technology research highlighted in Industrial Biotechnology journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... University and the University of Missouri are developing a ... useful byproducts at a cost of less than a ... the technological aspects of the project, the researchers are ... developing countries, since many areas with the greatest sanitation ...
... flu strain that emerged in China earlier this year has ... be reassured by this apparent lull in infections. The virus ... of a pathogen that may yet lead to a pandemic, ... and Infectious Diseases. David Morens, Jeffery Taubenberger, and Anthony Fauci, ...
... Boston As the population gets older, and the baby ... assume that the number of trips to the emergency department ... Brigham and Women,s Hospital (BWH), which shows that population aging ... to increase between now and 2050. However, visits will become ...
Cached Biology News:Pressure cooker on steroids treats human waste 2Pressure cooker on steroids treats human waste 3H7N9 influenza: History of similar viruses gives cause for concern 2H7N9 influenza: History of similar viruses gives cause for concern 3The aging population and emergency departments 2
(Date:8/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... the detection of foodborne pathogens, today announced that Paul ... Company Emerging Growth Conference on September 2 at 9:20am ... York Marriott Marquis. A live webcast ... relations section of Roka Bioscience,s website at http://rokabio.investorroom.com/ ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... Inc. today announced the,scheduled presentation of data from ... long-acting human growth hormone (hGH) analogue developed in,collaboration ... meeting in Rio de Janeiro. Andrew R. Hoffman, ... Affairs at Stanford University,will present the clinical results ...
... Incorporated (Nasdaq:,VICL) today reported financial results for the quarter ended ... $0.8 million, compared,with revenues of $0.4 million for the third ... 2008 was $9.8 million or $0.24 per share, compared,with $9.2 ... 2007., Revenues for the first nine months of 2008 ...
... - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or ... the three and nine-month periods ended September ... Oncolytics made a decision in early November ... using the combination of REOLYSIN(R) with,paclitaxel/carboplatin in ...
Cached Biology Technology:Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 9
... expression vectors, we in-troduced a new concept, namely ... tran-scriptional level at the T7 phage promoter, and ... the plasmid copy number, The main advantage of ... practically all of the outstanding features of the ...
Mouse monoclonal [34B12] to Nop5p + Nop58p - Nucleolar Marker ( Abpromise for all tested applications)....
... the ultimate tool for investigating dynamic events ... previously have been limited at wavelengths longer ... not transmit in the deep UV. HORIBA ... introduces a filter-based confocal system (the DynaMic) ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
Biology Products: